Inaktiver Wert

Andere Sprachen Sarepta Therapeutics Inc Nasdaq

Aktien

US0023461041

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

17.05.	SAREPTA THERAPEUTICS, INC. : Mizuho Securities bleibt bei seiner Kaufempfehlung	ZM
14.05.	SAREPTA THERAPEUTICS, INC. : Oppenheimer gibt eine Kauf-Bewertung ab	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sarepta Therapeutics : P.413-251 Seo et al. In situ biodistribution & localization of SRP-9003 in LGMD2ER4 Mice	10.05.
Sarepta Therapeutics - Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health	06.05.
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health	03.05.
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	02.05.
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 EPS $0.73, vs. Street Est of $0.30	01.05.
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $413.5M, vs. Street Est of $370.5M	01.05.
Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours	01.05.
Sarepta Therapeutics: Q1 Earnings Snapshot	01.05.
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments	01.05.
Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01.05.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.05.
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results	24.04.
REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition	04.04.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 29, 2024	01.04.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	29.03.
FDA greenlights Italfarmaco's drug for rare muscular dystrophy	21.03.
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program	20.03.
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	12.03.
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	07.03.
Sarepta Therapeutics to Present at Upcoming Investor Conferences	04.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sarepta Therapeutics Inc Nasdaq

Aktien

US0023461041

Andere Sprachen

Filter